Biocodex is committed to supporting patients with Dravet syndrome and their caregivers. We teamed up with the Dravet Syndrome Foundation to sponsor a special edition segment on “The Balancing Act” airing on Lifetime called “Behind the Mystery of Dravet Syndrome” to increase awareness of Dravet and its impact.
Biocodex manufactures a treatment option for patients with Dravet syndrome, DIACOMIT® (stiripentol). DIACOMIT is an effective, FDA-approved antiseizure medication developed specifically for seizures associated with Dravet syndrome in children 6 months and older (weighing 15 lb or more) and taking clobazam.
The most common adverse reactions were somnolence, decreased appetite, agitation, ataxia, decreased weight, hypotonia, nausea, tremor, dysarthria, and insomnia.1